Baseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonists.
about
Biologic therapies and bone loss in rheumatoid arthritis.Bone remodelling markers in rheumatoid arthritis.Biomarkers predicting a need for intensive treatment in patients with early arthritisThe relation between cartilage biomarkers (C2C, C1,2C, CS846, and CPII) and the long-term outcome of rheumatoid arthritis patients within the CAMERA trial.Effect of Osteoprotegerin and Dickkopf-Related Protein 1 on Radiological Progression in Tightly Controlled Rheumatoid Arthritis.Effects of Antitumor Necrosis Factor Therapy on Osteoprotegerin, Neopterin, and sRANKL Concentrations in Patients with Rheumatoid Arthritis.Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITYOsteonecrosis of the jaw in a Crohn's disease patient following a course of Bisphosphonate and Adalimumab therapy: a case report.Lymphangiogenesis, myeloid cells and inflammation.Effect of Tumor Necrosis Factor Inhibitor Therapy on Osteoclasts Precursors in Rheumatoid Arthritis.Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?Serum interleukin-6 and survivin levels predict clinical response to etanercept treatment in patients with established rheumatoid arthritis.
P2860
Q30243911-49546FB6-6852-4EA0-B1CF-44F85826870DQ33563068-70EDF1A3-EBE3-4712-A89E-B6EBD8FEF8BDQ34982012-518FA666-A19A-4C46-B4EA-5935971F9218Q35557805-15600A12-40DA-4975-B24E-CFDC36776B89Q36211891-8DB4F146-FB8C-4F29-A4D4-7482367CA52DQ36245404-7F154042-C26C-4BF1-9E93-90C9E7EEEE2EQ37315782-2F511602-F264-4463-BADE-720F2BDB3723Q37474234-D2F3C1A4-B100-4947-923E-8C66CB123204Q37754580-10B7CAFE-F395-4288-971B-50C38D49F859Q41883420-12A3CB2D-DD92-4938-B431-E62CB3D06B16Q42633541-E525E9B6-2922-4969-A360-26A3A22EE8D5Q50918813-8E6DDAE5-6708-4CE0-9AF8-919ACBE411A6
P2860
Baseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonists.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Baseline serum RANKL levels ma ...... treated with TNF antagonists.
@ast
Baseline serum RANKL levels ma ...... treated with TNF antagonists.
@en
type
label
Baseline serum RANKL levels ma ...... treated with TNF antagonists.
@ast
Baseline serum RANKL levels ma ...... treated with TNF antagonists.
@en
prefLabel
Baseline serum RANKL levels ma ...... treated with TNF antagonists.
@ast
Baseline serum RANKL levels ma ...... treated with TNF antagonists.
@en
P2093
P2860
P356
P1476
Baseline serum RANKL levels ma ...... treated with TNF antagonists.
@en
P2093
Alejandro Balsa
Ana M Ortiz
Armando Laffon
Eva G Tomero
Isidoro González-Alvaro
Javier Orte
Rosario García-Vicuña
P2860
P304
P356
10.1136/ARD.2007.071910
P407
P577
2007-07-31T00:00:00Z